New pan-EU HTA: How can biopharma navigate the joint clinical assessment?
By AmerisourceBergen
What biopharma companies need to know to plan effectively
The new European Union (EU) Health Technology Assessment (HTA) regulation was enacted in January 2022 with the primary objective of streamlining the clinical assessment process for EU member states' HTA bodies. Biopharma companies need to be aware of the clinical development and market access processes in this uncharted environment. Enter your information below to read about how biopharma can approach their planning more successfully.
.jpg?h=320&iar=0&w=540&useCustomFunctions=1¢erCrop=1&hash=DDA1D7BEE906940394C769FA6454A08B)